INVEST
min $100
VC-Backed
Raised $250K or more from a venture firm
Health Care Originals (HCO) is a venture-backed healthtech company on a mission to revolutionize the $83B respiratory care market.
HCO’s AI-powered virtual respiratory care platform is pioneering always-on, personalized care for the 690M+ sufferers of asthma and chronic obstructive pulmonary disease - the third leading cause of death globally.
Backed by leading venture funds Safar Partners and Chloe Capital, and with proven product-market fit, HCO’s patented non-invasive solution is ready to improve the quality of life for millions worldwide.
Health Care Originals is swiftly becoming a powerhouse player in respiratory care, with contracts signed for $5.5M in projected annual recurring revenue (ARR) based on recruiting just 4% of the total customers available to us and a growing waitlist of over 12,000 members representing $8M ARR in pipeline value.
Forward-looking projections are not guaranteed.
Chronic respiratory conditions are the third leading cause of death worldwide.
Every day in America, there are 30,000 asthma attacks, 15,600 COPD office visits, and 430 respiratory-related deaths.
Chronic respiratory conditions affect people of all ages but women, people of color, and lower-income populations are at the greatest risk. These groups are frequently underdiagnosed or misdiagnosed, increasing the risk of life-threatening emergencies. Barriers like inadequate healthcare access and insufficient screening further exacerbate these challenges, leading to 10-15 million Americans suffering in silence without treatment.
People living with these conditions struggle with daily tasks as flare-ups lead to heightened anxiety, panic, as well as frequent hospital visits. $47B in avoidable costs are spent annually on related outpatient, inpatient, office visits, and ER.
Families and care-givers suffer too as they help their loved ones navigate a broken healthcare system riddled with complexities in a daily battle.
Medication is also limited in its effectiveness as it often does not work the same for everyone. People living with these conditions need help beyond medication-only therapies to live well.
One-size-fits-all healthcare is failing. Inadequate healthcare access, deficient routine screening, and poor adherence to treatment plans have led to radical underdiagnosed and undertreated asthma and COPD.
The exacerbating effects of climate change, worsening air quality, extended allergy season, and a rapidly aging population are all contributing to a rise of respiratory diseases.
HCO is at the forefront of personalized respiratory care, bringing peace of mind and ease to respiratory disease management.
Our proprietary AI-powered virtual platform and undetectable wearables offer members never-before-seen insights and actionable data so they can take control of their respiratory care.
Supported by a network of pulmonologists, respiratory therapists, mental health therapists, and behavior change coaches available whenever and wherever needed, members are seeing phenomenal results.
Health Care Originals is doing for respiratory disease what continuous glucose monitoring has done for diabetes, enhancing member autonomy and outcomes.
Within 6 months, 100% of members report reduced wheezing and shortness of breath, 90% of members report improved sleep, and 67% of members experience NO attacks.
Health Care Originals is the world’s first company turning deep organ sounds into personalized and actionable care insights.
At the core of HCO’s breakthrough is the sophisticated application of acoustics technology, or auscultation, the same technology used by stethoscopes.
Previously, there was no way to capture subtle internal organ sounds in real life. Now, we combine coughs, lung sounds, wheezing, and breath sounds with activity, temperature, and other parameters to create an individual's personalized baseline. Then we can track when they are trending away from that baseline.
By leveraging AI and machine learning to enhance predictive analytics and enable early diagnosis, we’re turning organ sounds into powerful tools for individual care management and improving outcomes.
With 13 patents allowed and 10 pending, our data-rich, AI-powered insights enable personalized care at scale.
Our method, called Nightingale, offers an optimal combination of human guidance, digital delivery, and real-time health data from our wearable device. Over 1,000 members have benefited from this system, and 12,000 more are waiting to breathe easier.
The total addressable market for respiratory care surpasses $83B - and growing.
Health Care Originals’ proven and patented continuous health tracking platform has the potential to become as common as the thermometer in homes nationwide, and globally.
This new paradigm for care leveraging biomarkers from deep organ sounds has applications beyond respiratory care, for example in cardiology, gastroenterology, and osteology, all of which live at the intersection of rapidly growing markets with double-digit CAGRs:
Health Care Originals uses a Fee-for-Service model that initially targets B2B2C channels. Members pay annually, at a price point of $249-$529, with costs typically covered by insurance.
With your backing, we can serve the 12,000 members ALREADY on our waitlist, representing $6M in ARR pipeline value, and close FDA regulatory clearance for more use cases via the 510(k) pathway.
We’re also on track to build global partnerships for our products, with distributors lined up in 2 countries.
With these milestones unlocked, we are poised to reach projected annual revenues of $35M+ by 2026.
Future financial projections are not guaranteed.
Signed contracts will provide $5.5M in revenue by March 2026. These contracts allow us to sell to members while we are setting up a state-by-state network to enable billing as fee-for-service with existing reimbursement codes. Our signed contract is with an entity that has 400,000 Medicare members. CMS data shows that 14% of this population will have asthma and COPD. We take a conservative approach and say that only 4% of them will use our services, which gives us the conservative projected revenue of $5.8M.
Just as Lark, Hinge, and Lyra have achieved multi-billion-dollar valuations by redefining care delivery in their verticals, Health Care Originals is poised to transform respiratory disease management.
All of the health tech unicorns below have transitioned care from high cost medical interventions such as surgeons and clinical visits to more scalable expert care delivered through digital channels.
In addition, strategic acquisitions of health devices and care solutions, like the $225M acquisition of Propeller Health by ResMed, highlight the demand for innovative healthtech deals in the market. Although we are optimistic about our future, it's important to acknowledge that an exit is not guaranteed.
Every share you purchase in this campaign comes with additional penny warrants.
As part of your early bird investment, you'll be entitled to 1.5 times the number of shares you purchase in warrants. These warrants will be automatically exercised after you invest and converted into preferred shares, so you'll receive 2.5 shares for the price of 1 share + 3 cents. These are the same terms we've used to raise $1.2M from investors like Safar Partners and a large family office.
The math works like this: For every $100 invested, you get 65 Preferred Shares and 97 warrants. The warrants will automatically be exercised after you invest, so you receive 162 Preferred shares.
Post early bird, as part of your investment, you'll be entitled to 0.5 times the number of shares you purchase in warrants. Those will be automatically exercised after you invest, so you'll receive 1.5 shares for the price of 1 share + 1 cent. These are the same terms we've used to raise $1.2M from investors like Safar Partners and a large family office.
The math works like this: For every $100 invested, you get 65 Preferred shares and 32 warrants. The warrants will automatically be exercised after you invest, so you receive 97 Preferred shares.
Recent healthtech valuations and successful exit comparables validate the market's appetite and HCO’s dual pathway potential of achieving a high-value acquisition or pursuing a public offering, ensuring maximum flexibility in realizing the full potential of your investment.
HCO is already generating revenue and our products are being used daily. This means we have product-market fit and our technology is de-risked. We’ve overcome all hurdles faced by a typical hardware company, yet we chose to price this round conservatively to maximize value to our earliest investors. We’ve seen what happens when founders over-value their companies. By pricing this round conservatively, we’re setting us all up for success.
